Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
NLSP 
NLS Pharmaceutics AG (NLSP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/17/2025: NLSP (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $6
1 Year Target Price $6
| 0 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -53.91% | Avg. Invested days 28 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/17/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 9.01M USD | Price to earnings Ratio - | 1Y Target Price 6 |
Price to earnings Ratio - | 1Y Target Price 6 | ||
Volume (30-day avg) 1 | Beta 0.15 | 52 Weeks Range 1.30 - 6.97 | Updated Date 09/17/2025 |
52 Weeks Range 1.30 - 6.97 | Updated Date 09/17/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.63 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -111.41% | Return on Equity (TTM) -862.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 10175139 | Price to Sales(TTM) - |
Enterprise Value 10175139 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -3.02 | Shares Outstanding 4252020 | Shares Floating 1687887 |
Shares Outstanding 4252020 | Shares Floating 1687887 | ||
Percent Insiders 23.79 | Percent Institutions 7.19 |
Upturn AI SWOT
NLS Pharmaceutics AG
Company Overview
History and Background
NLS Pharmaceutics AG, founded in 2015, is a Swiss biopharmaceutical company focusing on the development of innovative therapies for attention deficit hyperactivity disorder (ADHD) and other neurological disorders. The company aims to address unmet medical needs through its proprietary formulations and drug delivery technologies.
Core Business Areas
- ADHD Therapeutics: Developing and commercializing pharmaceutical products for the treatment of ADHD, with a focus on novel formulations and improved patient outcomes.
- Neurological Disorders: Exploring potential therapies for other neurological disorders, leveraging its expertise in drug development and formulation science.
Leadership and Structure
The leadership team consists of experienced pharmaceutical executives and scientists. The company operates with a lean organizational structure, emphasizing efficient drug development and strategic partnerships.
Top Products and Market Share
Key Offerings
- Quilience: Quilience is NLS's lead product candidate, a controlled-release formulation of mazindol being developed for the treatment of ADHD. Market share data is not currently available as Quilience is in clinical development. Competitors include stimulant medications like Adderall (VYGVF), Ritalin (NVS), and non-stimulant medications like Strattera (LLY).
Market Dynamics
Industry Overview
The ADHD therapeutics market is a large and growing market, driven by increasing awareness, diagnosis rates, and treatment options. It is characterized by intense competition among established pharmaceutical companies and emerging biotech firms.
Positioning
NLS Pharmaceutics AG aims to differentiate itself through its novel formulations and drug delivery technologies, potentially offering improved efficacy and safety profiles compared to existing treatments.
Total Addressable Market (TAM)
The global ADHD market is expected to reach billions of dollars. NLS Pharmaceutics AG is positioned to capture a segment of this market with its innovative therapies, subject to successful clinical trials and regulatory approvals.
Upturn SWOT Analysis
Strengths
- Novel drug formulations
- Experienced management team
- Focus on unmet medical needs
- Proprietary drug delivery technologies
Weaknesses
- Limited financial resources
- Reliance on successful clinical trials
- No currently marketed products
- Small market capitalization
Opportunities
- Potential partnerships with larger pharmaceutical companies
- Expansion into new therapeutic areas
- Positive clinical trial results
- Regulatory approval of Quilience
Threats
- Competition from established pharmaceutical companies
- Clinical trial failures
- Regulatory hurdles
- Generic entry of existing ADHD medications
Competitors and Market Share
Key Competitors
- LLY
- NVS
- VYGVF
Competitive Landscape
NLS Pharmaceutics AG faces significant competition from established pharmaceutical companies with larger resources and marketed products. Its competitive advantage lies in its novel formulations and potentially improved efficacy and safety profiles.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is limited as the company is in the development stage.
Future Projections: Future growth is dependent on the successful development and commercialization of its product candidates. Analyst estimates are subject to change based on clinical trial outcomes and market conditions.
Recent Initiatives: Recent initiatives include advancing Quilience through clinical trials and exploring potential partnerships.
Summary
NLS Pharmaceutics AG is a development-stage biopharmaceutical company with a focus on ADHD therapeutics. Its strength lies in its novel drug formulations and experienced management team. Key challenges include limited financial resources and reliance on successful clinical trials. Future success depends on securing regulatory approval for Quilience and building strategic partnerships.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Company filings
- Industry reports
Disclaimers:
The data provided is for informational purposes only and should not be considered investment advice. The analysis is based on publicly available information and may be subject to change without notice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NLS Pharmaceutics AG
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2021-01-29 | Co-Founder, CEO & Director Mr. Alexander Zwyer M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://nlspharma.com |
Full time employees - | Website https://nlspharma.com | ||
NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience for the treatment of narcolepsy; and Nolazol for the treatment of ADHD. The company also develops NLS-4, a selective dopamine reuptake inhibitor treatment for the chronic fatigue associated with the symptoms of Long-COVID; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist for improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. It has licensing agreements with Pegasus Advanced Research for use of mazindol for the treatment of ADHD. NLS Pharmaceutics AG was incorporated in 2015 and is headquartered in Zurich, Switzerland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.